



Versatile Macrocyclic Platform for the Complexation of [(nat)Y/(90)Y]Yttrium and Lanthanide Ions

Charlene Harriswangler, Laura Caneda-Martínez, Olivier Rousseaux, David Esteban-Gómez, Olivier Fougère, Rosa Pujales-Paradela, Laura Valencia, M Isabel Fernández, Nicolas Lepareur, Carlos Platas-Iglesias

► To cite this version:

Charlene Harriswangler, Laura Caneda-Martínez, Olivier Rousseaux, David Esteban-Gómez, Olivier Fougère, et al.. Versatile Macrocyclic Platform for the Complexation of [(nat)Y/(90)Y]Yttrium and Lanthanide Ions. *Inorganic Chemistry*, 2022, 61 (16), pp.6209-6222. 10.1021/acs.inorgchem.2c00378 . hal-03659894

HAL Id: hal-03659894

<https://hal.science/hal-03659894>

Submitted on 20 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Versatile Macrocyclic Platform for the Complexation of [^{nat}Y/⁹⁰Y]Yttrium and Lanthanide Ions

Charlene Harriswangler, Laura Caneda-Martínez, Olivier Rousseaux, David Esteban-Gómez, Olivier Fougère, Rosa Pujales-Paradela, Laura Valencia, M. Isabel Fernández, Nicolas Lepareur, and Carlos Platas-Iglesias*



Cite This: *Inorg. Chem.* 2022, 61, 6209–6222



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: We report a macrocyclic ligand (H_3L^6) based on a 3,6,10,13-tetraaza-1,8(2,6)-dipyridinacyclotetradecaphane platform containing three acetate pendant arms and a benzyl group attached to the fourth nitrogen atom of the macrocycle. The X-ray structures of the YL^6 and TbL^6 complexes reveal nine coordination of the ligand to the metal ions through the six nitrogen atoms of the macrocycle and three oxygen atoms of the carboxylate pendants. A combination of NMR spectroscopic studies (1H , ^{13}C , and ^{89}Y) and DFT calculations indicated that the structure of the YL^6 complex in the solid state is maintained in an aqueous solution. The detailed study of the emission spectra of the EuL^6 and TbL^6 complexes revealed Ln^{3+} -centered emission with quantum yields of 7.0 and 60%, respectively. Emission lifetime measurements indicate that the ligand offers good protection of the metal ions from surrounding water molecules, preventing the coordination of water molecules. The YL^6 complex is remarkably inert with respect to complex dissociation, with a lifetime of 1.7 h in 1 M HCl. On the other hand, complex formation is fast (~ 1 min at pH 5.4, 2×10^{-5} M). Studies using the ^{90}Y -nuclide confirmed fast radiolabeling since $[^{90}Y]YL^6$ is nearly quantitatively formed (radiochemical yield (RCY) > 95) in a short time over a broad range of pH values from ca. 2.4 to 9.0. Challenging experiments in the presence of excess ethylenediaminetetraacetic acid (EDTA) and in human serum revealed good stability of the $[^{90}Y]YL^6$ complex. All of these experiments combined suggest the potential application of H_3L^6 derivatives as Y-based radiopharmaceuticals.



INTRODUCTION

Coordination chemistry plays a major role in biomedicine, as it provides an effective method for carrying metals inside living organisms allowing to take advantage of the extraordinary properties that are characteristic of some of these elements.¹ Nevertheless, the release of free metals into the body is, to say the least, undesirable in most cases.^{2,3} Consequently, ensuring the stability of these coordination compounds is essential to guarantee their safe delivery and excretion. To achieve this goal, macrocyclic ligands are often the preferred choice when designing this type of compound, since they usually give rise to higher thermodynamic stability, as well as superior kinetic inertness.^{4–7}

Undoubtedly, one of the most significant biomedical applications of macrocyclic complexes can be found in the field of biomedical imaging. With respect to the selection of metals, lanthanides have always been of paramount importance for the design of imaging agents in different techniques,⁸ and, given their unique luminescence properties (especially in the case of Eu^{3+} and Tb^{3+}), their suitability for the preparation of optical probes for imaging cells, tissues, and small animals must be highlighted.^{9,10} In this case, the macrocyclic ligand should

be designed not only to ensure the stability of the complex but also to maximize the photoluminescence quantum yield of the emission. As Ln^{3+} centers are known for their poor extinction coefficients, the ligand assumes the task of absorbing light through a suitable chromophore attached to its structure (commonly known as antenna), with this energy being subsequently transferred to the lanthanide ion. Additionally, it is imperative that the macrocycle wraps the metal competently to avoid solvent coordination and consequent quenching of luminescence.^{11–14}


Although it cannot be considered a lanthanide in its own right, yttrium is generally included in this group and, therefore, macrocycles that coordinate effectively with lanthanide ions are usually appropriate for binding with Y^{3+} .^{15–17} Nonetheless, for imaging purposes, the interest of this ion resides in its nuclear

Received: February 3, 2022

Published: April 14, 2022



Chart 1. Ligands Discussed in This Work




properties. Thus, the positron emitter ^{86}Y has been attracting attention over the last few years as a candidate for the design of radiopharmaceuticals for positron emission tomography (PET) due to its versatile half-life (14.74 h) and its well-known chelation chemistry. Moreover, the existence of the β^- emitter isotope ^{90}Y -yttrium allows for the design of theranostic agents, making yttrium an extremely interesting option in nuclear medicine.^{18,19} To construct a metal-based radiopharmaceutical, a bifunctional chelator is typically chosen, which is basically a chelating ligand provided with a linker capable of conjugation to a targeting vector.^{20,21} It must be noted that time is of the essence when working with decaying nuclides, so even though kinetic inertness with respect to dissociation is still fundamental, matching the kinetics of formation with the lifetime of the radioisotope is of paramount importance as well.^{22,23}

Apart from its decay properties, there are some additional nuclear attributes related to yttrium that can be found useful for medical imaging applications. The only natural isotope of yttrium, ^{89}Y , presents a spin quantum number of 1/2, being

therefore considered an NMR-active nucleus. Unfortunately, the extremely low gyromagnetic ratio ($\gamma = 2.0864 \text{ MHz/T}$) and the long longitudinal relaxation times (T_1) associated with this nucleus make the acquisition of ^{89}Y NMR spectra an almost unfeasible task.²⁴ Nonetheless, this weakness can be turned into strength thanks to a recently discovered technique: dynamic nuclear polarization (DNP). With the application of DNP-NMR, the unusually long T_1 translates into an extended polarization lifetime of nuclear spins, which produces an extraordinary increase in sensitivity. Moreover, ^{89}Y NMR spectra present sharp signals and high sensitivity of the chemical shift to the environment, making ^{89}Y compounds potentially attractive as magnetic resonance imaging (MRI) probes.^{25–29}

Among the macrocyclic systems available, azamacrocycles occupy a distinguished position, given that the nitrogen donor atoms present in their structure can be easily functionalized, enabling the incorporation of pendant arms that can be used to tune and control the properties of the metal, to bind to a targeted biomolecule or simply to add additional coordination

Scheme 1. Synthetic Procedure for the Preparation of LnL⁶ Complexes^a

^a(i) BaCl₂, MeOH, reflux, 4 h; (ii) NaBH₄, MeOH, 0 °C; (iii) benzyl bromide, H₂O, pH = 5–6; (iv) BrCH₂COO^tBu, K₂CO₃, CH₃CN; (v) CF₃COOH, CH₂Cl₂; (vi) Ln(OTf)₃/YCl₃, DIPEA, 1-butanol.

positions to increase the denticity of the ligand. Thus, the most popular macrocycles in biomedicine are those arising from the modification of the platforms tacn, cyclen, and cyclam, mainly by the inclusion of acetate pendant arms.⁴ Nevertheless, inserting pyridine moieties into the macrocyclic backbone may be worth considering since their introduction tends to increase rigidity in the ligand and to cause alterations in its basicity, leading to significant modifications in the thermodynamic and kinetic properties of its complexes.^{30–33} Accordingly, hexaazamacrocycles derived from the condensation of 2,6-diformylpyridine and ethylenediamine such as those depicted in Chart 1, have proven to successfully host lanthanide ions, due to their spacious macrocyclic cavity and their capacity to satisfy the coordination requirements of these large ions through the functionalization of their four secondary amines.^{34–43} Furthermore, it has been found that binding constants for H₄L¹ with large metal ions are considerably high (log *K* ~ 22) and promising indications of kinetic inertness also exist for H₄L¹, L³, and L⁵ lanthanide complexes.^{35,40,42}

Herein, we present a new nonadentate hexaazamacrocyclic ligand containing a benzyl group (H₃L⁶) and report its coordination ability toward the Y³⁺ ion as well as the luminescence properties of its Eu³⁺ and Tb³⁺ complexes. The formation and dissociation kinetics of the Y³⁺ complex have been studied by spectrophotometric measurements. The structure of the complexes in solution was assessed using a combination of multinuclear (¹H, ¹³C, ⁸⁹Y) NMR spectroscopy, time-resolved emission spectroscopy, and DFT calculations. We also report the X-ray structure of the Y³⁺ and Tb³⁺ complexes. Attention should be devoted to alkylation with the benzyl moiety, which could be selectively reversed through hydrogenation. As a result, once the secondary amine is recovered, it could be functionalized a second time with a group of a different nature, such as a linker capable of bioconjugation with a relevant macromolecule, or a more efficient antenna. Another possibility for functionalization is

through the para-carbon of this moiety, proving once more that this platform is quite versatile.⁴⁴ Consequently, ligand H₃L⁶ is expected to be a competent precursor of bifunctional chelators for Y-based radiopharmaceuticals as well as a suitable chelating agent for lanthanides for optical imaging.

RESULTS AND DISCUSSION

Synthesis of the Ligand and Metal Complexes. The preparation of ligand H₃L⁶ was achieved by following the synthetic procedure described in Scheme 1. Synthesis of the parent macrocycle **1** was completed by [2 + 2] condensation of ethylenediamine and 2,6-diformylpyridine, using BaCl₂ as a template agent, and subsequent reduction of imine moieties with sodium borohydride, as previously reported.⁴⁶ To obtain a nonadentate ligand, asymmetric functionalization of one NH group was carried out with benzyl bromide in water under controlled pH conditions. In this way, the monosubstituted derivative, compound **2**, was obtained. This allowed the introduction of three coordinating pendant arms by *N*-alkylation with *tert*-butyl 2-bromoacetate and later hydrolysis with TFA, to finally obtain ligand H₃L⁶ with a 6% overall yield starting from macrocycle **1** (three steps). This moderate result arises because of the poor yield achieved during the initial alkylation with benzyl bromide. Nevertheless, it must be taken into consideration that upon purification in this step, a large amount of unreacted parent macrocycle **1** was recovered, thereby compensating for the low efficiency of the procedure to some extent.

The reaction of H₃L⁶ with Ln(OTf)₃ (Ln = Eu or Tb) or YCl₃ salts in 1-butanol in the presence of DIPEA as a base afforded the corresponding charge-neutral LnL⁶ complexes in good yields (ca. 70%). The high-resolution mass spectra (ESI⁺) confirm the formation of the complexes (Figure S1, Supporting Information).

X-ray Crystal Structure Studies. Slow evaporation from aqueous solutions of the Y³⁺ and Tb³⁺ complexes provided




Figure 1. ORTEP⁴⁵ view of the structure of the YL⁶ and TbL⁶ complexes (50% ellipsoid probability). Hydrogen atoms and water molecules are omitted for simplicity.

colorless block-like crystals suitable for X-ray analysis. Figure 1 displays views of the molecular structures, while bond distances of the metal coordination environments are shown in Table 1. As it can be observed, ligand H₃L⁶ coordinates to

dron around the metal ion can be best described as a tricapped trigonal prism (Figure 2). This is confirmed by the quantitative

Table 1. Bond Distances (Å) of the Metal Coordination Environments in LnL⁶ Complexes (Ln = Y or Tb)

Y(1)–O(1)	2.3019(17)	Tb(1)–O(1)	2.320(4)
Y(1)–O(5)	2.3019(15)	Tb(1)–O(5)	2.382(6)
Y(1)–O(3)	2.3097(16)	Tb(1)–O(3)	2.315(2)
Y(1)–N(1)	2.5170(19)	Tb(1)–N(1)	2.534(2)
Y(1)–N(4)	2.5191(17)	Tb(1)–N(4)	2.518(5)
Y(1)–N(5)	2.5863(16)	Tb(1)–N(5)	2.664(5)
Y(1)–N(6)	2.6249(17)	Tb(1)–N(6)	2.700(5)
Y(1)–N(3)	2.6370(18)	Tb(1)–N(3)	2.582(5)
Y(1)–N(2)	2.6574(18)	Tb(1)–N(2)	2.601(7)

the metal centers through the six nitrogen atoms located in the macrocyclic backbone and the three oxygen atoms from the acetate pendant arms, thus resulting in a coordination number of nine. The chelate rings formed by the coordination of the ethylenediamine moieties adopt identical conformations, which can be described as $\lambda\lambda$ or $\delta\delta$. In YL⁶, the two centrosymmetrically related enantiomers are present in the crystal lattice. Crystals of the TbL⁶ contain both the $\lambda\lambda$ and $\delta\delta$ isomers in the asymmetric unit, presenting slightly different bond distances and angles. It has been shown that this type of arrangement favors the formation of a smaller macrocyclic cavity and, therefore, of shorter bonds.^{38,39} With respect to the relative disposition of the pyridyl units, it is known that ligands containing two pyridine moieties connected by an ethylenediamine bridge can present two types of conformations: the twist-wrap (tw), in which the planes that define the pyridyl entities are relatively twisted to each other, and the twist-fold (tf), where in addition to the twisting, an overall folding of the ligand over the metal is observed (Figure S2).⁴⁷ In this case, the complex exhibits a twist-fold conformation, which is evidenced by the lack of linearity of the N(4)–Y(1)–N(1) angle (148.5°). Once again, this is not surprising, as this kind of disposition has been previously observed in similar structures displaying nine-coordinate geometry.³⁶

The metal–N distances involving the N atoms of the pyridine units are similar to those observed for other nine-coordinated complexes of these metal ions containing pyridine units.^{48–51} The distances to the amine donor atoms of the macrocycle and the oxygen atoms of the carboxylate groups are also within the normal range observed for complexes with polyaminocarboxylate ligands.^{52–55} The coordination polyhe-




Figure 2. View of the tricapped trigonal prismatic coordination around the metal ion in YL⁶.

droon analysis carried out with the aid of the SHAPE program,^{56–60} which provides shape measures of 1.72 and 1.81 for YL⁶ and TbL⁶, respectively (a shape measure of 0 indicates a coordination polyhedron fully coincident with the reference polyhedron, while the maximum value of the shape measure is 100). The upper tripod of the trigonal prism is defined by the oxygen atoms of carboxylate groups O(5) and O(3) and the amine nitrogen atom N(5), while the lower tripod is delineated by N(1), N(3) and O(1). These two triangular faces are nearly parallel, intersecting at 4.0 (YL⁶) and 4.2° (TbL⁶). The N donor atoms (N(2), N(4), and N(6)) occupy the capping positions, defining N–(Y,Tb)–N angles in the range 117.3–122.8°, and thus are very close to the ideal values (120°).

Photophysical Properties of the Eu and Tb Complexes. The UV–vis absorption spectra of the TbL⁶ and EuL⁶ complexes in ca. 10^{−4} M aqueous solution (pH ~ 7) are depicted in Figure 3. In both cases, the absorption spectra consist of one broad band with a maximum at 268 nm that can be assigned to the $\pi \rightarrow \pi^*$ transition centered on the aromatic units of the ligand. Excitation into this absorption band led to the characteristic Ln³⁺ emission spectra displayed in Figure 3. Thus, TbL⁶ luminescence gives rise to a set of distinctive narrow bands located between 485 and 655 nm corresponding to the metal-centered ⁵D₄ → ⁷F_J transitions ($J = 6-3$), the most intense being placed at 542 nm ($J = 5$), as expected.⁶¹ On the other hand, the emission spectrum of EuL⁶ shows an array of bands in the range of 580–710 nm, in agreement with the typical ⁵D₀ → ⁷F_J transitions of this ion ($J = 0-4$). Particular




Figure 3. UV-vis absorption (dotted lines), excitation, and emission spectra of TbL⁶ (top) and EuL⁶ (bottom), recorded in H₂O solution (10^{−4} M, pH ~ 7) at room temperature.

attention must be given to the $^5D_0 \rightarrow ^7F_0$ transition band, whose relatively high intensity is an indication of the low symmetry of the complex. This statement is also supported by the high $^5D_0 \rightarrow ^7F_2/^5D_0 \rightarrow ^7F_1$ intensity ratio, which is known to be strongly correlated with a low level of symmetry. In addition, it must be highlighted that the spectrum shows a single $^5D_0 \rightarrow ^7F_0$ transition, as can be predicted due to the nondegeneracy of the 5D_0 and 7F_0 levels, suggesting the existence of a single Eu³⁺ species in solution. This is in accordance with the splitting patterns observed for $^5D_0 \rightarrow ^7F_1$ and $^5D_0 \rightarrow ^7F_2$ transitions since, due to the Stark effect, they can split at most into three and five components, respectively, for a single emitting compound.^{61,62} The presence of three components for the $^5D_0 \rightarrow ^7F_1$ transition is also clearly indicative of a low symmetry of the crystal field created by the ligand.⁶² The ten-coordinate [EuL³]³⁺ complex, which presents *D*₂ symmetry in solution, presents two components for the $^5D_0 \rightarrow ^7F_1$ transition, as well as unusually intense $^5D_0 \rightarrow ^7F_5$ and $^5D_0 \rightarrow ^7F_6$ transitions that are not observed for EuL⁶.⁴²

The excitation spectra recorded for both TbL⁶ and EuL⁶ complexes upon metal-centered emission are very similar to the corresponding absorption spectra, which indicates that the aromatic moieties in the ligand provide an efficient energy transfer to the metal center.⁶⁴ To determine the hydration state of TbL⁶ and EuL⁶ complexes, their luminescent lifetimes were measured upon emission at 617 and 542 nm, respectively, in both H₂O and D₂O solutions. The observed emission decays were fitted to monoexponential decay curves (Figure S3), and the resulting lifetime values were collected in Table 2. Calculation of the number of water molecules was possible through the use of Beeby⁶³ and Horrocks⁶⁵ equations, which

Table 2. Selected Photophysical Parameters for TbL⁶ and EuL⁶ Complexes in Aqueous Solution

	λ_{max} (nm) ^a	$\phi_{\text{H}_2\text{O}}$ (%)	$\tau_{\text{H}_2\text{O}}$ (ms)	$\tau_{\text{D}_2\text{O}}$ (ms)	q ^b
Tb	268 (9900)	60	2.41	2.63	−0.1
Eu	268 (8500)	7.0	1.18	1.64	0.0

^a λ_{max} , nm; ϵ , M^{−1} cm^{−1}. ^bHydration number calculated according to ref 63.

unambiguously led to hydration numbers of zero in both cases. The lifetimes of TbL⁶ measured in H₂O and D₂O solution are very similar, which leads to a small negative q value calculated with the expression provided by Beeby.⁶³ Thus, it can be concluded that the ligand is able to satisfy the coordination requirements of these ions, preventing solvent molecules from binding to the metal center and therefore fulfilling one of the most important conditions for becoming part of a suitable fluorescent probe.

The emission quantum yields of both TbL⁶ and EuL⁶ have been measured in 0.1 M Tris-buffered aqueous solutions at pH = 7.4 using Eu³⁺ and Tb³⁺ tris(dipicolinates) as standards.^{66,67} Predictably, TbL⁶ presents a quantum yield ($\phi_{\text{H}_2\text{O}}$ = 0.60) that is far superior to that observed for EuL⁶ ($\phi_{\text{H}_2\text{O}}$ = 0.07), likely because the energy of the ligand-centered triplet state presents a considerably higher energy than the emissive 5D_0 level of Eu³⁺. This is indeed expected, as the excited triplet state of pyridine (32 260 cm^{−1})⁶⁸ is much higher in energy than the 5D_0 level of Eu³⁺ (~17 240 cm^{−1}), while the optimal triplet state energy for efficient energy transfer was found to be 20 000–23 000 cm^{−1}.⁶⁹ The quantum yield determined for TbL⁶ is very high, comparable to those determined for $q = 0$ complexes containing picolinate moieties. Furthermore, the (long) lifetime of the 5D_4 excited state of Tb (2.41 ms) is also close to the values reported for highly luminescent Tb^{III} complexes that lack water molecules in the inner coordination sphere.^{31,70–74}

The quantum yield determined for EuL⁶ (7%) is comparable to that of [EuL³]³⁺ and represents a ~4-fold increase with respect to [EuL⁵]³⁺.^{42,43} This can be attributed to the quenching effect of the hydroxyl groups of the ligand coordinated to the metal ion in the latter. The [EuL⁴]³⁺ complex displays a considerably lower quantum yield (0.1%) associated with the quenching effect of an excited charge transfer state.⁴³

To gain further understanding of the energy transfer process in EuL⁶, the metal-centered emission quantum yield was calculated following the procedure developed by Werts et al.⁷⁵ Unfortunately, this method can only be applied to Eu³⁺ complexes, as it is based on the strong magnetic dipole nature of the $^5D_0 \rightarrow ^7F_1$ transition found in these compounds. Therefore, the intensity of this band can be considered independent of the chemical environment of the metal center and eq 1 can be applied for the calculation of the radiative lifetime τ_R , where $A_{\text{MD},0} = 14.65 \text{ s}^{-1}$ is the spontaneous emission probability of the $^5D_0 \rightarrow ^7F_1$ transition, n is the refractive index of the medium (1.333 for water at 589.3 nm), and $I_{\text{tot}}/I_{\text{MD}}$ is the ratio of the integrated corrected emission spectra to the area of the $^5D_0 \rightarrow ^7F_1$ transition.^{66,73,75}

$$\frac{1}{\tau_R} = A_{\text{MD},0} n^3 \frac{I_{\text{tot}}}{I_{\text{MD}}} \quad (1)$$

The value of 6.55 ms found for τ_R is similar to those reported in the literature for nine-coordinated Eu^{III} complexes.^{76–80} The quantum yield of the luminescence step (ϕ_{Eu}) can be subsequently obtained using eq 2 since the lifetime of the Eu complex in water ($\tau_{\text{H}_2\text{O}}$) is known (Table 2).

$$\phi_{\text{Eu}} = \frac{\tau_{\text{H}_2\text{O}}}{\tau_R} \quad (2)$$

This analysis gives $\phi_{\text{Eu}} = 0.18$, which yields a sensitization efficiency (η_{sens}) of 0.39 using eq 3. This suggests that the EuL^6 complex presents a modest efficiency of the energy transfer taking place from the excited states of the ligand.^{72,73} Nevertheless, this analysis should be taken with caution, as $A_{\text{MD},0}$ values that depart significantly from that proposed by Werts were recently determined.⁸¹

$$\phi_{\text{H}_2\text{O}} = \eta_{\text{sens}} \times \phi_{\text{Eu}} \quad (3)$$

Solution Structure. The diamagnetic character of YL^6 allowed for a more thorough analysis of its solution structure using NMR spectroscopy (^1H , ^{13}C , and ^{89}Y). A rather complex ^1H NMR spectrum was found for YL^6 due to the low symmetry of the molecule (C_1). Nonetheless, a comparison with the spectra of the free ligand (Figure S4) corroborates the formation of the complex, not only by the chemical shifts that can be observed but also by the extensive increment in the number of signals caused by the increase in the rigidity of the molecule upon coordination. The $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum (Figure S5) exhibits the 29 signals expected for a single species in solution. Interestingly, two of the signals arising from carbonyl groups appear as doublets because of coupling with ^{89}Y ($^2J_{\text{C-Y}} \sim 2$ Hz), evidencing the coordination of the acetate groups to the metal center.

The ^{89}Y NMR shift of the YL^6 complex was measured using ^1H , ^{89}Y HMQC experiments, which provide easy access to ^{89}Y NMR shifts, avoiding the long acquisition times required to obtain conventional ^{89}Y NMR spectra.²⁴ The ^1H , ^{89}Y HMQC spectrum showed cross-peaks relating the ^{89}Y nuclei with several proton nuclei of the ligand, providing an ^{89}Y NMR chemical shift of 154.7 ppm (Figure 4). The ^{89}Y shifts were found to be very sensitive to the number and nature of the donor atoms coordinated to the metal ion, but rather insensitive to the coordination geometry. Indeed, a relationship

between the observed ^{89}Y NMR shifts and nature of the donor atoms of the ligand has been established from the analysis of chemical shift data of a wide range of complexes with polyaminopolycarboxylate ligands.⁸²

$$\delta^{\text{calc}}(^{89}\text{Y}) = A - (S_{\text{Nam}} \cdot n_{\text{Nam}} + S_{\text{Npy}} \cdot n_{\text{Npy}} + S_{\text{Oc}} \cdot n_{\text{Oc}}) \quad (4)$$

where A is an empirical constant that was determined to be 863 ppm; S_{Nam} , S_{Npy} , and S_{Oc} represent the shielding contribution of amine nitrogen atoms, pyridyl nitrogen atoms, and carboxylate oxygen atoms, respectively; and n_{Nam} , n_{Npy} , and n_{Oc} are the number of donor atoms of each type. Using $S_{\text{Nam}} = 68.1$, $S_{\text{Npy}} = 85.7$, and $S_{\text{Oc}} = 94.0$, with $n_{\text{Nam}} = 4$, $n_{\text{Npy}} = 2$, and $n_{\text{Oc}} = 3$, we obtained a calculated ^{89}Y shift of $\delta^{\text{calc}} = 137$ ppm, which is in good agreement with the experimental shift. These results unambiguously confirm the coordination of the ligand to the metal ion through its N_6O_3 donor set and exclude the presence of coordinated water molecules (a coordinated water molecule contributes with ca. 107 ppm to the shielding of the ^{89}Y resonance).⁸²

DFT calculations were performed for the LnL^6 systems ($\text{Ln} = \text{Eu}$, Tb , and Y) with the purpose of understanding the geometries exhibited by these compounds. As previously stated, this type of systems can present a twist-wrap (tw) or a twist-fold (tf) conformation depending on the relative disposition of the pyridyl units. Adopting one or another can induce important changes in the properties of these compounds, and therefore a comparative study between both geometries was conducted. The calculated geometries obtained for YL^6 are shown in Figure S2, while bond lengths of the metal coordination spheres found for all of the systems are listed in Table S1 (Supporting Information). An excellent agreement was found for the calculated bond distances with respect to the values obtained by means of X-ray diffraction for the twist-fold conformation of the YL^6 complex. The calculated free energies favor the twist-fold conformation for the three complexes, with $\Delta G^{\text{o,calc}} = \Delta G^{\text{o}}(\text{tw}) - \Delta G^{\text{o}}(\text{tf})$ values of 1.8, 2.9, and 4.1 kcal mol^{−1} for EuL^6 , TbL^6 , and YL^6 , respectively. Thus, the twist-fold conformation is increasingly stabilized as the ion size decreases. A quick analysis of the bond lengths reveals that the twist-fold arrangement allows for shorter bonds and this reduction with respect to the twist-wrap disposition becomes more pronounced with smaller metal centers. This is in line with the behavior mentioned above for related compounds,^{38,39} which evinces that the ligand changes its conformation as the radius of the metal ion decreases so the macrocyclic cavity is reduced, and therefore shorter bonds are favored. Relativistic DFT calculations using the DKH2 Hamiltonian (see computational details below) and the methodology described previously provided calculated ^{89}Y NMR shifts of 154.6 and 120.9 ppm for the twist-fold and twist-wrap forms, respectively. The first value is in excellent agreement with the experimental value of 154.7 ppm, which confirms that the YL^6 complex adopts a twist-fold structure in solution.

Dissociation and Formation Kinetics. A high stability of the complex is usually the most crucial requirement for *in vivo* applications of coordination compounds, as both the free ligand and the metal ion are often toxic. Nonetheless, even though thermodynamic parameters are important aspects to evaluate their stability, nowadays it is widely recognized that a slow dissociation of the complex is more important than a high stability constant.²³ Acid decomplexation experiments have




Figure 4. ^1H , ^{89}Y HMQC NMR spectrum of YL^6 recorded in D_2O solution (pH \sim 7.0, 25 $^\circ\text{C}$).

become a popular method to preliminarily assess the kinetic inertness of coordination compounds as well as to provide a means of comparison between different ligands. Since most complexes dissociate easily under strongly acidic conditions, the acid-catalyzed process is the main dissociation pathway found for the macrocyclic complexes usually employed for this type of applications.^{51,72,83} Accordingly, the acid-catalyzed dissociation rate of YL^6 was studied at 25 °C in 0.1 to 2.4 M HCl solutions. The absorption spectra of the ligand and its Y^{3+} complex are noticeably different, as a bathochromic shift can be detected upon coordination (Figure S6). Hence, the dissociation process has been studied following the variations in absorbance at 268 nm.

Figure 5 shows the plot of the observed dissociation rates (k_{obs}) vs HCl concentration, which indicates the existence of a




Figure 5. Dissociation rates (k_{obs}) determined for YL^6 as a function of HCl concentration (25 °C).

linear correlation between these two parameters. Therefore, the experimental values obtained could be fitted to eq 5

$$k_{\text{obs}} = k_0 + k_1[\text{H}^+] \quad (5)$$

where k_0 is a constant that describes the spontaneous dissociation, while k_1 characterizes the specific acid-catalysis dissociation. These results suggest that the dissociation occurs through the formation of a monoprotonated species, probably by protonation of one of the acetate pendant arms followed by proton transfer to one of the N atoms of the macrocyclic ring, subsequently displacing the metal ion from the macrocyclic cavity.⁸³ The fitting procedure of the data yields a negligible (within statistical error) value for k_0 , which is a sign of the minor importance of spontaneous dissociation in the process, as expected under strongly acidic conditions, where protonation is favored. Consequently, the data were analyzed setting k_0 to zero, obtaining a value for $k_1 = (1.13 \pm 0.02) \times 10^{-4} \text{ M}^{-1} \text{ s}^{-1}$.

The values of the rate constants listed in Table 3 indicate that YL^6 presents a higher kinetic inertness than YPCTA^{83} and YDO3A^{86} . The rate constant characterizing the proton-assisted dissociation pathway k_1 is 1 order of magnitude lower for YL^6 than for YPCTA , while YDO3A is even more labile under acidic conditions. The half-lives of these complexes calculated from the rate constants confirm the higher inertness of YL^6 compared with YPCTA and YDO3A , indicating that YL^6 presents a remarkable kinetic inertness with respect to complex dissociation. The GdDOTA complex is however more inert than YL^6 .

The rates of complexation of Y^{3+} by the L^6 ligand were assessed in aqueous solutions buffered at pH values in the range 4.7–5.4. Pseudo-first-order conditions were ensured

Table 3. Dissociation Rates and Half-Lives ($t_{1/2}$) of YL^6 and Related Complexes

	k_0 (s^{-1})	k_1 ($\text{M}^{-1} \text{s}^{-1}$)	$t_{1/2}$ (s) ^e
$(\text{L}^6)^{3-}$	0	$1.13(2) \times 10^{-4}$	6.1×10^3
PCTA^{3-a}	0	1.07×10^{-3}	1.2×10^3
$\text{DOTA}^{4-b,c}$	5×10^{-10}	2×10^{-6}	3.5×10^5
DO3A^{3-d}	0	5.2×10^{-2}	13

^aRef 83. Second-order dependence on proton-ion concentration with third-order rate constant $k_2 = 6.32 \times 10^{-4} \text{ M}^{-2} \text{ s}^{-1}$ was observed.

^bData for the Gd complex from ref 84. ^cKinetic data for the $[\text{}^{90}\text{Y}]\text{YDOTA}^-$ complex at 310 K were reported in ref 85. ^dData from ref 86. ^eCalculated at $[\text{H}^+] = 1 \text{ M}$ as $t_{1/2} = \ln 2/k_{\text{obs}}$.

using an excess of the metal ion (10–40 equiv). The reaction was followed by monitoring the changes in the absorption spectrum of the ligand caused by metal complexation. The reaction was found to be very fast under these conditions, as it was nearly complete (~90%) within only one minute (Figure S7). However, given the faint spectral changes caused by complexation, we also performed kinetic experiments using Tb^{3+} and luminescent measurements. These results confirmed a very fast complexation process, which is complete within less than one minute. Thus, these results indicate that the complexes of L^6 are formed very quickly, in contrast to the corresponding DOTA derivatives and non-macrocyclic rigidified DTPA derivatives, as it has been shown that labeling of these ligands with $^{86/90}\text{Y}$ -nuclides required either rather harsh conditions (heating at 75–90 °C) or extended reaction times.²³

Radiolabeling Experiments. All of the results above prompted the assessment of the suitability of H_3L^6 for the preparation of ^{90}Y -based radiopharmaceuticals. The influence of reaction conditions for radiolabeling of H_3L^6 with yttrium-90 was ascertained by varying the reaction time, temperature, ligand concentration, and pH (Figure 6). The ligand (1.26–126 μg ; 0.002–0.2 μmol) was dissolved in ethanol and then reacted with yttrium-90 diluted in various acetate buffers. After 5 min, the radiochemical yield reached $86.9 \pm 2.26\%$ at RT and $98.6 \pm 0.14\%$ by heating to 80 °C (Figure 6A). Heating at least to 40 °C seems to be necessary to obtain a sufficient RCY but heating over 60 °C does not improve this value (Figure 6B). With a ligand concentration below 1 mM, heating to 40 °C appears to be insufficient, while heating to 60 °C leads to a better RCY (Figure 6C). $[\text{}^{90}\text{Y}]\text{YL}^6$ can be synthesized over a broad range of pH (Figure 6D). Radiolabeling results confirm those obtained with ^{89}Y , since $[\text{}^{90}\text{Y}]\text{YL}^6$ is almost quantitatively formed in 5 min at pH = 5.2, at 60 °C (RCY = $95.5 \pm 0.57\%$). HPLC analyses indicate $[\text{}^{90}\text{Y}]\text{YL}^6$ is the sole product formed (Figure S8). Fast reaction kinetics is an advantage when preparing radiopharmaceuticals, especially if working with short-lived isotopes. The performance of H_3L^6 in terms of radiolabeling efficiency with the $[\text{}^{90}\text{Y}]\text{Y}^{3+}$ ion is similar to those reported for PCTA analogues containing picolinate units replacing carboxylate pendant arms.³¹ In contrast, the formation of $[\text{}^{90}\text{Y}]\text{YDOTA}$ requires heating to 60 °C at pH 7.5.⁸⁷

$[\text{}^{90}\text{Y}]\text{YL}^6$ Stability. The stability of $[\text{}^{90}\text{Y}]\text{YL}^6$ in a competitive medium (ethylenediaminetetraacetic acid (EDTA) 100 mM) and in human serum was investigated. For these studies, $[\text{}^{90}\text{Y}]\text{YL}^6$ was prepared using optimized conditions. A solution of $[\text{}^{90}\text{Y}]\text{YL}^6$ was either diluted with an aqueous solution (v/v: 1/1) containing a large excess of the




Figure 6. (A) ^{90}Y -radiolabeling kinetics ($C_L = 1$ mM, pH 5.2, 20, and 80 °C), (B) variable temperature ($C_L = 1$ mM, pH 5.2, $t = 15$ min), (C) variation of the ligand concentration (pH 5.2, $t = 15$ min, 40 and 60 °C), and (D) pH variation, using 1 M acetate buffers ($C_L = 1$ mM, $t = 15$ min, 60 °C).

competitive EDTA ligand (100 equiv) or in 1 mL of human serum. The mixtures were incubated at 37 °C. Aliquots were taken at different time points (0, 1, 2, 5, 24, 48, and 120 h for the EDTA challenge; 0, 24, 48, 72, 96, and 168 h for serum stability) and analyzed by thin-layer chromatography (TLC). The evolution of the RCP (%) over time is represented in Figure 7.




Figure 7. Stability of ^{90}Y -YL⁶ (10–20 μM) in an excess of EDTA (100 equiv) and in human serum.

Radiochemical purity (RCP) of ^{90}Y -YL⁶ recorded over time indicates that the complexes remain remarkably stable in the presence of EDTA. There is no dissociation or transchelation for up to 5 days, which confirms the high kinetic inertness of the YL⁶ complex (Figure S9). Similarly, ^{90}Y -YL⁶ remains stable for over a week in the presence of human serum.

CONCLUSIONS

We have shown that ligand H₃L⁶ can be regarded as a suitable platform for the coordination of large metal ions such as Y³⁺, Tb³⁺, and Eu³⁺. According to the kinetic studies, the studied complexes show good inertness with respect to dissociation, making it possible to consider these compounds for biomedical applications. The remarkable kinetic inertness of these complexes is particularly striking considering the large size of the 18-membered macrocyclic unit of the ligand. Indeed, to the best of our knowledge only 12-membered macrocycles such as DOTA and PCTA, as well as certain cryptands, were found to form kinetically inert complexes with the Ln³⁺ ions (and Y³⁺).

Thus, the results reported in this work pave the way for a new generation of macrocyclic ligands for the stable complexation of these metal ions. In addition, the formation rates of the YL⁶ complex exceed those of YDOTA and rigidified YDTPA derivatives,²³ and therefore ligand H₃L⁶ could be especially valuable as a precursor for the design of yttrium-based radiopharmaceuticals.

On the other hand, according to the X-ray analyses and the calculations shown in this work, the resulting complexes tend to adopt geometries that favor the reduction of the macrocyclic cavity. Consequently, the ligand effectively wraps the metal ion, hindering the entrance of solvent molecules into the coordination sphere. As a result, quenching of luminescence is minimized for the TbL⁶ and EuL⁶ complexes, therefore meeting the key requirements for optical imaging applications.

In summary, ligand H₃L⁶ exhibits appropriate characteristics to be considered a useful platform for the design of different types of diagnostic and/or therapeutic probes. Furthermore, the possibility of functionalizing the ligand through the benzyl moiety or replacing it with other groups expands the range of possible specific applications for systems derived from this one, resulting in a remarkably versatile ligand.

EXPERIMENTAL AND COMPUTATIONAL SECTION

General Considerations. NMR spectra were obtained at 25 and 70 °C on a Bruker Avance 300, Bruker Avance 400, or Bruker Avance 500 spectrometer. Elemental analyses were performed on a Thermo Finnigan Flash EA 1112 elemental analyzer. IR spectra were recorded using a Thermo Scientific FT-IR Nicolet iS10 spectrophotometer equipped with a Thermo Scientific Smart iTR attenuated total reflectance (ATR) accessory. Mass spectra were obtained either using an LC-Q-q-TOF Applied Biosystems QSTAR Elite spectrometer or an LTQ-Orbitrap Discovery mass spectrometer coupled to a Thermo Accela HPLC in ESI positive mode. Medium performance liquid chromatography (MPLC) was performed in a Puriflash XS 420 InterChim Chromatographer equipped with a UV-DAD detector and a 20 g BGB Aquarius C18AQ reversed-phase column (100 Å, spherical, 15 μm). Aqueous solutions of the final compounds were lyophilized in a Biobase BK-FD10 Series vacuum freeze dryer.

Absorption and Emission Spectra. UV–vis spectra were recorded on a Jasco V-650 spectrophotometer using 1 cm cells. Emission and excitation spectra were measured on a Horiba FluoroMax Plus-P spectrofluorometer equipped with a 150 W ozone-free xenon arc lamp and an R928P photon counting emission detector, as well as a photodiode reference detector for monitoring lamp output. Luminescence decays were measured on the same instrument working in the phosphorescence mode using a xenon flash lamp. Hydration numbers (q) were calculated using eq 6, where $\tau_{\text{H}_2\text{O}}$ and $\tau_{\text{D}_2\text{O}}$ represent the luminescence decay lifetimes in water and deuterated water, respectively. For TbL⁶, the hydration number was calculated using $A = 5.0$ and $B = 0.06$,⁶³ while for EuL⁶, the reported hydration number corresponds to that obtained with $A = 1.2$ and $B = 0.25$.⁶³ The use of $A = 1.11$ and $B = 0.31$ provides essentially the same result ($q = -0.08$).⁶⁵

$$q = A[(1/\tau_{\text{H}_2\text{O}} - 1/\tau_{\text{D}_2\text{O}}) - B] \quad (6)$$

Luminescence quantum yields were obtained using Eu³⁺ and Tb³⁺ tris(dipicolinates) as references in solutions at 7.5×10^{-5} and 6.5×10^{-5} M, respectively ($\phi^{\text{Eu}} = 0.24$ and $\phi^{\text{Tb}} = 0.22$, $\lambda_{\text{exc}} = 279$ nm), while samples were measured at 1×10^{-4} M. Both the samples and the references were measured in 0.1 M Tris-buffered aqueous solutions at pH = 7.4.^{66,67}

Dissociation and Formation Kinetics. Acid-catalyzed dissociation kinetics of YL⁶ were studied under pseudo-first-order conditions by the addition of concentrated HCl to an aqueous solution of the complex (2×10^{-5} M) at 25 °C. HCl concentration was varied in the range 0.1–2.4 M. Dissociation was followed by monitoring the decrease of the absorbance at 268 nm as a function of time using a Biochrom Libra S70 UV–vis spectrophotometer. The data were fitted to eq 7

$$A_t = A_e + (A_0 - A_e)e^{-kt} \quad (7)$$

where A_t , A_e , and A_0 are the absorbance values measured at time t , at equilibrium, and at $t = 0$, respectively.

The formation of the YL⁶ complex was assessed by the addition of an excess of metal ion (10–40 equiv) to an aqueous solution of the ligand at 2×10^{-5} M and following the increase in absorbance at 275 nm over time until equilibrium was reached. Similarly, the formation of TbL⁶ was monitored by analyzing the emission intensity at 541 nm over time, with the aid of an SLM AMINCO Bowman series 2 luminescence spectrometer. The studies were performed in both cases at 25 °C with ionic strength adjusted to 0.1 M with KCl and *N*-methylpiperazine as a buffer to maintain the pH constant (4.7–5.4).

Syntheses. All solvents and reagents used were purchased from commercial sources, had reagent-grade quality, and were used as supplied, without further purification except for macrocycle **1**, which was prepared according to the previously reported procedure.⁴⁶

3-Benzyl-3,6,10,13-tetraaza-1,8(2,6)-dipyridinacyclotetradecaphane (2). Compound **1** (0.2737 g, 0.84 mmol) was suspended in H₂O (100 mL). The pH was lowered to 5 using 6 M HCl. As the pH is lowered, compound **1** dissolves completely. Benzyl bromide (0.1434, 0.84 mmol) was slowly added to the mixture, forming a suspension. The reaction mixture was then kept stirring at room temperature for 11 days, maintaining the pH between 5 and 6. The solvent was removed in a rotary evaporator to give a brown oil, which was dissolved in a mixture of H₂O containing 0.1% of TFA (2 mL) and purified by MPLC using Method A (Table S2, Supporting Information). Compound eluted at 41% CH₃CN, (retention time: 9.18 column volumes, 11:53 min:s). The combined fractions containing compound **2** were then freeze-dried obtaining 74.1 mg of a hygroscopic white-brown solid. Yield: 21%. ¹H NMR (300 MHz, D₂O): δ 8.0 (t, 1H), 7.9 (t, 1H), 7.4 (m, 9H), 4.6 (m, 6H), 4.5 (s, 2H), 4.4 (s, 2H), 3.8 (m, 8H). ¹³C{¹H} NMR (75 MHz, D₂O): δ 150.40, 150.23, 150.21, 149.83, 139.75, 139.62, 131.29, 129.31, 129.04, 128.15, 124.25, 123.03, 122.94, 58.38, 56.91, 50.91, 50.79, 43.91, 43.85, 42.31. MS (ESI⁺, %BPI): m/z 417.277 (100) ([C₂₅H₃₃N₆]⁺), 439.258 (26) ([C₂₅H₃₂N₆Na]⁺). Calc. for [C₂₅H₃₃N₆]⁺: 417.276; [C₂₅H₃₂N₆Na]⁺: 439.258.

2, 2', 2''-(13-Benzyl-3,6,10,13-tetraaza-1,8(2,6)-dipyridinacyclotetradecaphane-3,6,10-triyl) Triacetic Acid (H₃L⁶). Compound **2** (0.065 g, 0.156 mmol) was dissolved in CH₃CN (20 mL). K₂CO₃ (0.067 g, 0.484 mmol) and KI (2.59 mg, 0.0156 mmol) were added to the resulting mixture and, after stirring for 30 min, a solution of *tert*-butyl 2-bromoacetate (0.0913 g, 0.468 mmol) in acetonitrile (5 mL) was added dropwise over the course of 1 h. The mixture was stirred at room temperature for 3 days and then was concentrated to dryness. The resulting residue was dissolved in water (30 mL) and the pH of the solution was adjusted with NaOH to an approximate value of 13. This aqueous solution was extracted with chloroform (3 \times 30 mL). The combined organic extracts were dried over Na₂SO₄ and evaporated to dryness, obtaining a brown oil. The resulting product was dissolved in a 1:1 CH₂Cl₂/TFA solution (3 mL) and stirred for 24 h at room temperature. The solvent was removed under a flow of nitrogen obtaining a brown residue that was washed with water (6 \times 3 mL). This residue was then purified by reversed-phase MPLC method B (Table S3, Supporting Information). Compound eluted at 35% CH₃CN, (retention time: 8.86 column volumes, 12:07 min:s). The combined fractions were freeze-dried obtaining 0.0392 g of H₃L⁶ as a white powder. Yield: 28%. ¹H NMR (400 MHz, D₂O, pD = 1.0, 343 K) δ 8.8 (t, 1H), 8.4 (t, 1H), 8.2 (d, 2H), 7.9 (d, 1H), 7.8 (m, 6H), 5.2 (s, 2H), 5.0 (m, 6H), 5.0 (s, 2H), 4.4 (s, 2H), 4.3 (d, 6H), 4.1 (d, 4H), 4.1 (m, 2H). ¹³C{¹H} NMR (126 MHz D₂O, pD 1.0): δ 172.66, 170.82, 150.71, 150.18, 148.10, 140.03, 131.68, 130.32, 128.84, 127.53, 126.09, 124.84, 123.69, 123.16, 59.87, 58.80, 56.95, 56.61, 55.98, 55.71, 54.91, 53.26, 52.01, 50.33, 50.02. Elem. anal. found: C, 48.20; H, 4.48; N, 9.23. Calc. for C₃₁H₃₈N₆O₆·2.8TFA: C, 48.31; H, 4.52; N, 9.24. IR (ATR, cm⁻¹): ν 2924, 2853 (C–H), 1725 (C=O), 1667 (C=N), 1457, 1397 (C=C), 1173, 1127 (C–O). MS (ESI⁺, %BPI): m/z 591.293 (100) ([C₃₁H₃₉N₆O₆]⁺), 629.240 (19) ([C₃₁H₃₈KN₆O₆]⁺), 613.275 (18) ([C₃₁H₃₈NaN₆O₆]⁺). Calc. For [C₃₁H₃₉N₆O₆]⁺: 591.293; [C₃₁H₃₈KN₆O₆]⁺: 629.248; [C₃₁H₃₈NaN₆O₆]⁺: 613.275.

General Procedure for the Preparation of LnL⁶ Complexes.

A mixture of H₃L⁶ (0.075 g, 0.067 mmol) and DIPEA (0.063 g, 0.49 mmol) in 1-butanol (6 mL) was stirred for 30 min. Ln(OTf)₃ (Ln = Eu, Tb) or YCl₃·6H₂O (0.067 mmol) was added to the solution, and the mixture was heated to reflux for 8 h. The solvent was removed in a rotary evaporator, and the resultant residue was purified by column chromatography (SiO₂, CH₃CN/H₂O 14:3). The product obtained was dissolved in CH₃CN (20 mL) and passed through a filter with a 0.22 μ m pore size. The filtrate was concentrated to dryness and washed with diethyl ether.

EuL⁶: Yield: 0.036 g, 70%. Elem. anal. found: C, 46.64; H, 4.84; N, 9.32. Calc. for C₃₁H₃₅EuN₆O₆·3H₂O: C, 46.91; H, 5.21; N, 10.59. MS (ESI⁺, %BPI): m/z 763.17 (100) ([C₃₁H₃₅EuN₆NaO₆]⁺), 741.19 (48) ([C₃₁H₃₆EuN₆O₆]⁺). HR-MS (ESI⁺): 741.1930. Calc. for [C₃₁H₃₆EuN₆O₆]⁺: 741.1903.

TbL⁶: Yield: 0.040 g, 74%. Elem. anal. found: C, 45.71; H, 5.25; N, 9.70. Calc. for C₃₁H₃₅N₆O₆Tb·4H₂O: C, 45.48; H, 5.29; N, 10.27. MS (ESI⁺, %BPI): m/z 769.18 (100) ([C₃₁H₃₅N₆NaO₆Tb]⁺), 747.20 (20) ([C₃₁H₃₆N₆O₆Tb]⁺). HR-MS (ESI⁺): 747.1965. Calc. for [C₃₁H₃₆N₆O₆Tb]⁺: 747.1944.

YL⁶: Yield: 0.033 g, 66%. ¹H NMR (D₂O, pD = 7.5, 300 MHz): δ 7.92 (m, 2H), 7.46–7.24 (m, 9H), 4.86 (m, 1H), 4.35–3.91 (m, 7H), 3.74–3.52 (m, 4H), 3.35 (m, 3H), 3.16–2.63 (m, 7H), 2.46 (d, 1H), 1.29 (d, 1H). ¹³C{¹H} NMR (D₂O, pD = 7.5, 125.8 MHz): δ 181.5 (d, ²J = 2.1 Hz), 180.5, 179.5 (d, ²J = 2.0 Hz), 159.7, 159.4, 156.0, 155.1, 141.4, 140.5, 131.9, 131.4, 128.6, 128.4, 122.9, 122.6, 122.2, 120.1, 65.6, 64.8, 64.3, 63.1, 62.0, 61.7, 58.8, 57.9, 57.6, 54.9, 54.4, 53.1. Elem. anal. found: C, 49.61; H, 5.13; N, 10.43. Calc. for C₃₁H₃₅N₆O₆Y·4H₂O: C, 49.74; H, 5.79; N, 11.23. MS (ESI⁺, %BPI): m/z 699.16 (100) ([C₃₁H₃₅N₆NaO₆Y]⁺), 677.18 (14) ([C₃₁H₃₆N₆O₆Y]⁺). HR-MS (ESI⁺): 677.1756. Calc. for [C₃₁H₃₆N₆O₆Y]⁺: 677.1749.

Crystal Structure Determinations. Crystallographic data were collected at 100 K using a Bruker D8 Venture diffractometer with a Photon 100 CMOS detector and Mo K α radiation ($\lambda = 0.71073$ Å) generated by an Incoatec high-brilliance microfocus source equipped

with Incoatec Helios multilayer optics. The software APEX3⁸⁸ was used for collecting frames of data, indexing reflections, and the determination of lattice parameters, SAINT⁸⁹ for integration of intensity of reflections, and SADABS⁹⁰ for scaling and empirical absorption correction. The structure was solved by dual-space methods using the program SHELXT.⁹¹ All nonhydrogen atoms were refined with anisotropic thermal parameters by full-matrix least-squares calculations on F^2 using the program SHELXL-2014.⁹² Hydrogen atoms were inserted at calculated positions and constrained with isotropic thermal parameters. The OLEX2 solvent mask routine was used to delete highly disordered water molecules from the model in both structures. CCDC 2143076 and 2143077 contain the supplementary crystallographic data for YL⁶ and TbL⁶ respectively. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. Table S4 contains the crystallographic data and the structure refinement parameters.

Computational Details. Full-geometry optimizations of the complexes studied in this work were performed using DFT within the hybrid meta-generalized gradient approximation with the TPSSH exchange–correlation functional⁹³ and the Gaussian 09 package (Revision D.01).⁹⁴ The ligand atoms were described using the standard 6-31G(d,p) basis set, while for the metal ions, an effective core potential (ECP) was employed to take into account the main relativistic effects and reduce the computational cost of the calculations. In the case of yttrium, the quasi-relativistic effective core potential ECP28MWB developed by Preuß and co-workers was used, along with its associated valence-basis set, which employs an (8s7p6d2f1g)/(6s5p3d2f1g)-GTO contraction scheme.^{95,96} The lanthanide ions were defined using the large-core quasi-relativistic effective core potential (LCRECP) created by Dolg and co-workers, which includes 46 + 4fⁿ core electrons in the core ($n = 6$ for Eu³⁺ and $n = 8$ for Tb³⁺) and explicitly describes the 11 outer electrons (5s, 5p, 5d, and 6s). The valence electrons were described using the associated (7s 6p 5d)/(5s 4p 3d)-GTO basis set.⁹⁷ The calculations were carried out in aqueous solutions and solvent effects were included making use of the integral-equation formalism variant of the polarizable continuum model (IEFPCM).⁹⁸ As a starting point, molecular systems generated with GaussView⁹⁹ were employed. Additionally, frequency analyses were performed on the optimized geometries to guarantee that they indeed correspond to energy minima rather than saddle points.

Using these optimized geometries, the ⁸⁹Y NMR shielding tensors were calculated with the ORCA program package (version 4.2.1)^{100,101} utilizing the GIAO^{102,103} method and the TPSSH functional.⁹³ Relativistic effects were considered applying the second-order Douglas–Kroll–Hess (DKH2) method,^{104,105} with the old-DKH-TZVPP basis set used by previous versions of ORCA consisting in a recontracted form of Ahlrichs' TZVPPAll basis set¹⁰⁶ for DKH2 calculations. The RIJK approximation, which considers both Coulomb and exchange-type integrals, was used for the calculation of the self-consistent field and the NMR chemical shielding constants.^{107–109} Auxiliary basis sets were constructed automatically by ORCA with the Autoaux procedure.¹¹⁰ The TightSCF and Grid7 (for Y) options were applied to increase the convergence tolerances and integration accuracies of the calculations from the defaults. Chemical shifts were determined as $\delta = (\sigma^{\text{ref}} - \sigma)$ considering the shielding constant calculated for [Y(H₂O)₈]³⁺·16H₂O as in ref 41. The calculations were carried out in aqueous solution and solvent effects were considered using the SMD solvation model.¹¹¹

Radiolabeling Studies. Yttrium-90 chloride ([⁹⁰Y]YCl₃) was provided by PerkinElmer Life Sciences (Waltham, MA) in a 0.05 M HCl solution. The activity of the ⁹⁰Y-solution comprised between 200 μ Ci and 1.2 mCi (7.5–45.5 MBq). Other chemicals (solvents, buffer solutions) were bought from Sigma-Aldrich (Saint-Louis, MO) and used as received. Experiments were performed in borosilicated sealed glass flasks. Sealed flasks were heated on a Bioblock heating block (Thermo Fisher, Waltham, MA). Activities were measured with a CRC-127R (Capintec, Inc., Ramsey, NJ) dose calibrator. Radiochemical yields (RCY) were determined by thin-layer chromatog-

raphy (TLC) on Whatman 1 paper (GE Healthcare, Maidstone, U.K.) eluted in MeOH with 0.1% NEt₃ and measured with a Cyclone Storage Phosphorimager (PerkinElmer, Waltham, MA), using the Optiquant software. HPLC analyses were performed on an HPLC Dionex Ultimate 3000 (Sunnyvale, CA) equipped with a diode array detector and a radiochromatographic fLumo (Berthold Technologies GmbH, Bad Wildbad, Germany) detector piloted by the Chromeleon software. The chromatographic analytic system employs an Accucore C₁₈ 100 \times 3 mm², 2.6 μ m column with A = H₂O; B = acetonitrile as eluents; 0–3 min: 100% A, 3–20 min: 0–90% B, 20–25 min: 90% B, 25–26 min: 90–0% B, 26–30 min: 100% A, at a flow rate of 0.4 mL/min.

⁹⁰Y-Radiolabeling. Yttrium-90 is a pure high-energy β -emitting nuclide. Experiments were done in a controlled area adapted for the manipulations of such elements, by trained and suitably equipped and monitored operators (finger and chest dosimeters, direct reading personal device). Operations were done inside a high-energy hotcell, using dedicated high-energy tungsten shielding for vials, syringes, and telescopic pliers. Several parameters such as concentration of ligands, volume and pH of the reaction mixture, incubation time, and temperature were varied extensively to obtain an optimized protocol. An [⁹⁰Y]YCl₃ solution (0.2 mL) in 1 M glacial acetic acid solution (pH = 2.4) or in 3 M acetate buffer (pH = 4.65–9) was added to 0.2 mL of H₃L⁶ ligand solution ($c = 10 \mu\text{M}$ –1 mM) in ethanol. The resulting solution was heated at 20–100 °C for 5–60 min.

Stability of the [⁹⁰Y]YL⁶ Radiochelate. For the challenging experiments, aliquots (0.2 mL) of [⁹⁰Y]YL⁶ solution prepared under an optimized procedure were mixed with 0.2 mL of a 100 mM EDTA solution. The mixture was incubated at 37 °C under slight stirring and analyzed on TLC after 0, 1, 2, 5, 24, 48, and 120 h. Each sample was analyzed in triplicate.

For the stability study in serum, aliquots (0.2 mL) of [⁹⁰Y]YL⁶ solution prepared under optimized procedure were mixed with 1 mL of a human serum. The mixture was incubated at 37 °C under slight stirring. A 100 μ L aliquot was taken and, after denaturing serum protein with an equal amount of absolute ethanol and centrifugation (3500g, 4 °C, 15 min), the supernatant was analyzed on TLC after 24, 48, 72, 96, and 168 h. Each sample was analyzed in triplicate.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.inorgchem.2c00378>.

Luminescence lifetime decay curves; ¹H, ¹³C, and ¹H–¹H COSY NMR spectra; high-resolution MS; kinetic experiments; absorption spectra; bond distances; and optimized geometries obtained with DFT (PDF)

Accession Codes

CCDC 2143076–2143077 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

■ AUTHOR INFORMATION

Corresponding Author

Carlos Platas-Iglesias – Centro de Investigaciones Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain; orcid.org/0000-0002-6989-9654; Email: carlos.platas.iglesias@udc.es

Authors

Charlene Harriswangler – Centro de Investigaciones Científicas Avanzadas (CICA) and Departamento de Química,

Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain

Laura Caneda-Martínez – Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain

Olivier Rousseaux – Groupe Guerbet, Centre de Recherche d'Aulnay-sous-Bois, 95943 Roissy CdG, France

David Esteban-Gómez – Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain

Olivier Fougère – Groupe Guerbet, Centre de Recherche d'Aulnay-sous-Bois, 95943 Roissy CdG, France

Rosa Pujales-Paradela – Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain

Laura Valencia – Departamento de Química Inorgánica, Facultad de Ciencias, Universidade de Vigo, 36310 Pontevedra, Spain

M. Isabel Fernández – Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain

Nicolas Lepareur – Univ Rennes, Centre Eugène Marquis, Inrae, Inserm, Institut NUMECAN (Nutrition, Métabolismes et Cancer)—UMR_A 1341, UMR_S 1241, F-35000 Rennes, France

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.inorgchem.2c00378>

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

C.P.-I., and D.E.-G. thank Ministerio de Ciencia e Innovación (Grant PID2019-108352RJ-I00) and Xunta de Galicia (Grant ED431B 2020/S2) for generous financial support. The authors are indebted to Centro de Supercomputación de Galicia (CESGA) for providing the computer facilities. C.H. thanks Ministerio de Ciencia e Innovación (Grant PRE2020-092888) and Xunta de Galicia (Grant ED481A 2021/070) for funding her PhD contracts. N.L. acknowledges Labex IRON (grant no. ANR-11-LABX-0018) and Guerbet for financial support. L.V. is indebted to CACTI (Universidade de Vigo) for X-ray measurements. Funding for open access provided by Universidade da Coruña/CISUG.

REFERENCES

- (1) Franz, K. J.; Metzler-Nolte, N. Introduction: Metals in Medicine. *Chem. Rev.* **2019**, *119*, 727–729.
- (2) Gaynor, D.; Griffith, D. M. The Prevalence of Metal-Based Drugs as Therapeutic or Diagnostic Agents: Beyond Platinum. *Dalton Trans.* **2012**, *41*, 13239–13257.
- (3) Guo, Z.; Sadler, P. J. Metals in Medicine. *Angew. Chem., Int. Ed.* **1999**, *38*, 1512–1531.
- (4) Mewis, R. E.; Archibald, S. J. Biomedical Applications of Macrocyclic Ligand Complexes. *Coord. Chem. Rev.* **2010**, *254*, 1686–1712.
- (5) Stasiuk, G. J.; Long, N. J. The Ubiquitous DOTA and Its Derivatives: The Impact of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid on Biomedical Imaging. *Chem. Commun.* **2013**, *49*, 2732.
- (6) Clough, T. J.; Jiang, L.; Wong, K.-L.; Long, N. J. Ligand Design Strategies to Increase Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents. *Nat. Commun.* **2019**, *10*, No. 1420.
- (7) Dai, L.; Jones, C. M.; Chan, W. T. K.; Pham, T. A.; Ling, X.; Gale, E. M.; Rottle, N. J.; Tai, W. C.-S.; Anderson, C. J.; Caravan, P.; Law, G.-L. Chiral DOTA Chelators as an Improved Platform for Biomedical Imaging and Therapy Applications. *Nat. Commun.* **2018**, *9*, No. 857.
- (8) Wahsner, J.; Gale, E. M.; Rodríguez-Rodríguez, A.; Caravan, P. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. *Chem. Rev.* **2019**, *119*, 957–1057.
- (9) Amoroso, A. J.; Pope, S. J. A. Using Lanthanide Ions in Molecular Bioimaging. *Chem. Soc. Rev.* **2015**, *44*, 4723–4742.
- (10) Hamon, N.; Roux, A.; Beyler, M.; Mulatier, J.-C.; Andraud, C.; Nguyen, C.; Maynadier, M.; Bettache, N.; Duperray, A.; Grichine, A.; Brasselet, S.; Gary-Bobo, M.; Maury, O.; Tripiet, R. Pyclyen-Based Ln(III) Complexes as Highly Luminescent Bioprobes for *In Vitro* and *In Vivo* One- and Two-Photon Bioimaging Applications. *J. Am. Chem. Soc.* **2020**, *142*, 10184–10197.
- (11) Armelao, L.; Quici, S.; Barigelletti, F.; Accorsi, G.; Bottaro, G.; Cavazzini, M.; Tondello, E. Design of Luminescent Lanthanide Complexes: From Molecules to Highly Efficient Photo-Emitting Materials. *Coord. Chem. Rev.* **2010**, *254*, 487–505.
- (12) Coogan, M. P.; Pope, S. J. A. Application of D- and f-Block Fluorescent Cell Imaging Agents. In *The Chemistry of Molecular Imaging*; John Wiley & Sons, Ltd., 2014; pp 275–298.
- (13) Bünzli, J. G. Lanthanide Luminescence for Biomedical Analyses and Imaging. *Chem. Rev.* **2010**, *110*, 2729–2755.
- (14) Horrocks, W. D.; Sudnick, D. R. Lanthanide Ion Probes of Structure in Biology. Laser-Induced Luminescence Decay Constants Provide a Direct Measure of the Number of Metal-Coordinated Water Molecules. *J. Am. Chem. Soc.* **1979**, *101*, 334–340.
- (15) Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease. *Chem. Rev.* **2010**, *110*, 2858–2902.
- (16) Jannin, S.; Helm, L.; Bodenhausen, G. Kinetics of Yttrium–Ligand Complexation Monitored Using Hyperpolarized ⁸⁹Y as a Model for Gadolinium in Contrast Agents. *J. Am. Chem. Soc.* **2010**, *132*, 5006–5007.
- (17) Le Fur, M.; Rottle, N. J.; Correcher, C.; Clavijo Jordan, V.; Ross, A. W.; Catana, C.; Caravan, P. Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents. *Angew. Chem., Int. Ed.* **2020**, *59*, 1474–1478.
- (18) Tickner, B. J.; Stasiuk, G. J.; Duckett, S. B.; Angelovski, G. The Use of Yttrium in Medical Imaging and Therapy: Historical Background and Future Perspectives. *Chem. Soc. Rev.* **2020**, *49*, 6169–6185.
- (19) Carter, K. P.; Deblonde, G. J.-P.; Lohrey, T. D.; Bailey, T. A.; An, D. D.; Shield, K. M.; Lukens, W. W.; Abergel, R. J. Developing Scandium and Yttrium Coordination Chemistry to Advance Theranostic Radiopharmaceuticals. *Commun. Chem.* **2020**, *3*, No. 61.
- (20) Kostelnik, T. I.; Orvig, C. Radioactive Main Group and Rare Earth Metals for Imaging and Therapy. *Chem. Rev.* **2019**, *119*, 902–956.
- (21) Boros, E.; Packard, A. B. Radioactive Transition Metals for Imaging and Therapy. *Chem. Rev.* **2019**, *119*, 870–901.
- (22) Zeglis, B. M.; Lewis, J. S. A Practical Guide to the Construction of Radiometallated Bioconjugates for Positron Emission Tomography. *Dalton Trans.* **2011**, *40*, 6168–6195.

- (23) Price, E. W.; Orvig, C. Matching Chelators to Radiometals for Radiopharmaceuticals. *Chem. Soc. Rev.* **2014**, *43*, 260–290.
- (24) Löble, M. W.; Casimiro, M.; Thielemann, D. T.; Oña-Burgos, P.; Fernández, I.; Roesky, P. W.; Breher, F. ^1H , ^{89}Y HMQC and Further NMR Spectroscopic and X-Ray Diffraction Investigations on Yttrium-Containing Complexes Exhibiting Various Nuclearities. *Chem. - Eur. J.* **2012**, *18*, 5325–5334.
- (25) Merritt, M. E.; Harrison, C.; Kovacs, Z.; Kshirsagar, P.; Malloy, C. R.; Sherry, A. D. Hyperpolarized ^{89}Y Offers the Potential of Direct Imaging of Metal Ions in Biological Systems by Magnetic Resonance. *J. Am. Chem. Soc.* **2007**, *129*, 12942–12943.
- (26) Jindal, A. K.; Merritt, M. E.; Suh, E. H.; Malloy, C. R.; Sherry, A. D.; Kovács, Z. Hyperpolarized ^{89}Y Complexes as Ph Sensitive NMR Probes. *J. Am. Chem. Soc.* **2010**, *132*, 1784–1785.
- (27) Lumata, L.; Merritt, M.; Malloy, C.; Sherry, A. D.; Kovacs, Z. Fast Dissolution Dynamic Nuclear Polarization NMR of ^{13}C -Enriched ^{89}Y -DOTA Complex: Experimental and Theoretical Considerations. *Appl. Magn. Reson.* **2012**, *43*, 69–79.
- (28) Lumata, L.; Jindal, A. K.; Merritt, M. E.; Malloy, C. R.; Sherry, A. D.; Kovacs, Z. DNP by Thermal Mixing under Optimized Conditions Yields >60 000-Fold Enhancement of ^{89}Y NMR Signal. *J. Am. Chem. Soc.* **2011**, *133*, 8673–8680.
- (29) Wang, Q.; Parish, C.; Niedbalski, P.; Ratnakar, J.; Kovacs, Z.; Lumata, L. Hyperpolarized ^{89}Y -EDTMP Complex as a Chemical Shift-Based NMR Sensor for Ph at the Physiological Range. *J. Magn. Reson.* **2020**, *320*, No. 106837.
- (30) Rezaeivala, M.; Keypour, H. Schiff Base and Non-Schiff Base Macrocyclic Ligands and Complexes Incorporating the Pyridine Moiety – The First 50 Years. *Coord. Chem. Rev.* **2014**, *280*, 203–253.
- (31) Le Fur, M.; Molnár, E.; Beyler, M.; Fougère, O.; Esteban-Gómez, D.; Rousseaux, O.; Tripier, R.; Tircsó, G.; Platas-Iglesias, C. Expanding the Family of Pycen-Based Ligands Bearing Pendant Picolinate Arms for Lanthanide Complexation. *Inorg. Chem.* **2018**, *57*, 6932–6945.
- (32) Garda, Z.; Molnár, E.; Hamon, N.; Barriada, J. L.; Esteban-Gómez, D.; Váradi, B.; Nagy, V.; Pota, K.; Kálmán, F. K.; Tóth, I.; Lihi, N.; Platas-Iglesias, C.; Tóth, É.; Tripier, R.; Tircsó, G. Complexation of Mn(II) by Rigid Pycen Diacetates: Equilibrium, Kinetic, Relaxometric, Density Functional Theory, and Superoxide Dismutase Activity Studies. *Inorg. Chem.* **2021**, *60*, 1133–1148.
- (33) Nizou, G.; Favaretto, C.; Borgna, F.; Grundler, P. V.; Saffon-Merceron, N.; Platas-Iglesias, C.; Fougère, O.; Rousseaux, O.; van der Meulen, N. P.; Müller, C.; Beyler, M.; Tripier, R. Expanding the Scope of Pycen-Picolinate Lanthanide Chelates to Potential Theranostic Applications. *Inorg. Chem.* **2020**, *59*, 11736–11748.
- (34) Kim, W. D.; Kiefer, G. E.; Maton, F.; McMillan, K.; Muller, R. N.; Sherry, A. D. Relaxometry, Luminescence Measurement, Electrophoresis, and Animal Biodistribution of Lanthanide(III) Complexes of Some Polyaza Macrocyclic Acetates Containing Pyridine. *Inorg. Chem.* **1995**, *34*, 2233–2243.
- (35) Miao, L.; Bell, D.; Rothremel, G. L.; Bryant, L. H.; Fitzsimmons, P. M.; Jackels, S. C. Design and Synthesis of an “Ultraschelating” Ligand Based on an 18-Membered Ring Hexaaza Macrocyclic. *Supramol. Chem.* **1996**, *6*, 365–373.
- (36) Valencia, L.; Martínez, J.; Macías, A.; Bastida, R.; Carvalho, R. A.; Geraldes, C. F. G. C. X-Ray Diffraction and ^1H NMR in Solution: Structural Determination of Lanthanide Complexes of a $\text{Py}_2\text{N}_6\text{Ac}_4$ Ligand. *Inorg. Chem.* **2002**, *41*, 5300–5312.
- (37) Bligh, S. W. A.; Choi, N.; Geraldes, C. F. G. C.; Knoke, S.; McPartlin, M.; Sangane, M. J.; Woodroffe, T. M. A Novel Hexaaza Macrocyclic with Methylenebisphosphonate Pendant Arms: A Potential Useful Chelate for Biomedical Applications†. *J. Chem. Soc., Dalton Trans.* **1997**, *0*, 4119–4126.
- (38) Núñez, C.; Bastida, R.; Macías, A.; Mato-Iglesias, M.; Platas-Iglesias, C.; Valencia, L. A Hexaaza Macrocyclic Ligand Containing Acetohydrazide Pendants for Ln(III) Complexation in Aqueous Solution. Solid-State and Solution Structures and DFT Calculations. *Dalton Trans.* **2008**, *102*, 3841–3850.
- (39) del C. Fernández-Fernández, M.; Bastida, R.; Macías, A.; Pérez-Lourido, P.; Platas-Iglesias, C.; Valencia, L. Lanthanide(III) Complexes with a Tetrapyrroline Pendant-Armed Macrocyclic Ligand: ^1H NMR Structural Determination in Solution, X-Ray Diffraction, and Density-Functional Theory Calculations. *Inorg. Chem.* **2006**, *45*, 4484–4496.
- (40) Castro, G.; Regueiro-Figueroa, M.; Esteban-Gómez, D.; Bastida, R.; Macías, A.; Pérez-Lourido, P.; Platas-Iglesias, C.; Valencia, L. Exceptionally Inert Lanthanide(III) PARACEST MRI Contrast Agents Based on an 18-Membered Macrocyclic Platform. *Chem. - Eur. J.* **2015**, *21*, 18662–18670.
- (41) Castro, G.; Wang, G.; Gambino, T.; Esteban-Gómez, D.; Valencia, L.; Angelovski, G.; Platas-Iglesias, C.; Pérez-Lourido, P. Lanthanide(III) Complexes Based on an 18-Membered Macrocyclic Containing Acetamide Pendants. Structural Characterization and PARACEST Properties. *Inorg. Chem.* **2021**, *60*, 1902–1914.
- (42) Gambino, T.; Valencia, L.; Pérez-Lourido, P.; Esteban-Gómez, D.; Zaiss, M.; Platas-Iglesias, C.; Angelovski, G. Inert Macrocyclic Eu^{3+} Complex with Affirmative ParaCEST Features. *Inorg. Chem. Front.* **2020**, *7*, 2274–2286.
- (43) Nonat, A.; Esteban-Gómez, D.; Valencia, L.; Pérez-Lourido, P.; Barriada, J. L.; Charbonnière, L. J.; Platas-Iglesias, C. The Role of Ligand to Metal Charge-Transfer States on the Luminescence of Europium Complexes with 18-Membered Macrocyclic Ligands. *Dalton Trans.* **2019**, *48*, 4035–4045.
- (44) Price, E. W.; Zeglis, B. M.; Cawthray, J. F.; Ramogida, C. F.; Ramos, N.; Lewis, J. S.; Adam, M. J.; Orvig, C. H_4octa -Trastuzumab: Versatile Acyclic Chelate System for ^{111}In and ^{177}Lu Imaging and Therapy. *J. Am. Chem. Soc.* **2013**, *135*, 12707–12721.
- (45) Farrugia, L. J. WinGX and ORTEP for Windows: An Update. *J. Appl. Crystallogr.* **2012**, *45*, 849–854.
- (46) Rothermel, G. L.; Miao, L.; Hill, A. L.; Jackels, S. C. Macrocyclic Ligands with 18-Membered Rings Containing Pyridine or Furan Groups: Preparation, Protonation, and Complexation by Metal Ions. *Inorg. Chem.* **1992**, *31*, 4854–4859.
- (47) Ferreirós-Martínez, R.; Esteban-Gómez, D.; Platas-Iglesias, C.; de Blas, A.; Rodríguez-Blas, T. Zn(II), Cd(II) and Pb(II) Complexation with Pyridinecarboxylate Containing Ligands. *Dalton Trans.* **2008**, *17*, 5754–5765.
- (48) Carter, K. P.; Pope, S. J. A.; Cahill, C. L. A Series of Ln-p-Chlorobenzoic Acid–Terpyridine Complexes: Lanthanide Contraction Effects, Supramolecular Interactions and Luminescent Behavior. *CrystEngComm* **2014**, *16*, 1873–1884.
- (49) Lewis, F. W.; Harwood, L. M.; Hudson, M. J.; Drew, M. G. B.; Modolo, G.; Sypula, M.; Desreux, J. F.; Bouslimani, N.; Vidick, G. Interaction of 6,6'-Bis(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-1,2,4-Benzotriazin-3-yl)-2,2':6',2''-Terpyridine (CyMe₄-BTTP) with Some Trivalent Ions Such as Lanthanide(III) Ions and Americium(III). *Dalton Trans.* **2010**, *39*, 5172–5182.
- (50) Kiefer, G. E.; Woods, M. Solid State and Solution Dynamics of Pyridine Based Tetraaza-Macrocyclic Lanthanide Chelates Possessing Phosphonate Ligating Functionality (Ln-PCTMB): Effect on Relaxometry and Optical Properties. *Inorg. Chem.* **2009**, *48*, 11767–11778.
- (51) Le Fur, M.; Beyler, M.; Lepareur, N.; Fougère, O.; Platas-Iglesias, C.; Rousseaux, O.; Tripier, R. Pycen Tri-*n*-Butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to ^{90}Y Radiolabeling. *Inorg. Chem.* **2016**, *55*, 8003–8012.
- (52) Kumar, K.; Chang, C. A.; Francesconi, L. C.; Dischino, D. D.; Malley, M. F.; Gougoutas, J. Z.; Tweedle, M. F. Synthesis, Stability, and Structure of Gadolinium(III) and Yttrium(III) Macrocyclic Poly(Amino Carboxylates). *Inorg. Chem.* **1994**, *33*, 3567–3575.
- (53) Kotek, J.; Rudovský, J.; Hermann, P.; Lukeš, I. Three in One: TSA, TSA', and SA Units in One Crystal Structure of a Yttrium(III) Complex with a Monophosphinated H_4dota Analogue. *Inorg. Chem.* **2006**, *45*, 3097–3102.
- (54) Lau, E. Y.; Lightstone, F. C.; Colvin, M. E. Environmental Effects on the Structure of Metal Ion–DOTA Complexes: An Ab

Initio Study of Radiopharmaceutical Metals. *Inorg. Chem.* **2006**, *45*, 9225–9232.

(55) Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. *Chem. Rev.* **1999**, *99*, 2293–2352.

(56) Casanova, D.; Cirera, J.; Llunell, M.; Alemany, P.; Avnir, D.; Alvarez, S. Minimal Distortion Pathways in Polyhedral Rearrangements. *J. Am. Chem. Soc.* **2004**, *126*, 1755–1763.

(57) Cirera, J.; Ruiz, E.; Alvarez, S. Shape and Spin State in Four-Coordinate Transition-Metal Complexes: The Case of the D₆ Configuration. *Chem. - Eur. J.* **2006**, *12*, 3162–3167.

(58) Pinsky, M.; Avnir, D. Continuous Symmetry Measures. 5. The Classical Polyhedra. *Inorg. Chem.* **1998**, *37*, 5575–5582.

(59) Ruiz-Martínez, A.; Casanova, D.; Alvarez, S. Polyhedral Structures with an Odd Number of Vertices: Nine-Atom Clusters and Supramolecular Architectures. *Dalton Trans.* **2008**, *99*, 2583–2591.

(60) Ruiz-Martínez, A.; Casanova, D.; Alvarez, S. Polyhedral Structures with an Odd Number of Vertices: Nine-Coordinate Metal Compounds. *Chem. - Eur. J.* **2008**, *14*, 1291–1303.

(61) Richardson, F. S. Terbium(III) and Europium(III) Ions as Luminescent Probes and Stains for Biomolecular Systems. *Chem. Rev.* **1982**, *82*, 541–552.

(62) Binnemans, K. Interpretation of Europium(III) Spectra. *Coord. Chem. Rev.* **2015**, *295*, 1–45.

(63) Beeby, A.; Clarkson, I. M.; Dickins, R. S.; Faulkner, S.; Parker, D.; Royle, L.; Sousa, A. S.; de Williams, J. A. G.; Woods, M. Non-Radiative Deactivation of the Excited States of Europium, Terbium and Ytterbium Complexes by Proximate Energy-Matched OH, NH and CH Oscillators: An Improved Luminescence Method for Establishing Solution Hydration States. *J. Chem. Soc., Perkin Trans. 2* **1999**, *2*, 493–504.

(64) Sabbatini, N.; Guardigli, M.; Lehn, J.-M. Luminescent Lanthanide Complexes as Photochemical Supramolecular Devices. *Coord. Chem. Rev.* **1993**, *123*, 201–228.

(65) Supkowski, R. M.; Horrocks, W. D. On the Determination of the Number of Water Molecules, *q*, Coordinated to Europium(III) Ions in Solution from Luminescence Decay Lifetimes. *Inorg. Chim. Acta* **2002**, *340*, 44–48.

(66) Chauvin, A.; Frédéric, G.; Daniel, I.; Bünzli, J. G. Europium and Terbium Tris(Dipicolinates) as Secondary Standards for Quantum Yield Determination. *Spectrosc. Lett.* **2004**, *37*, 517–532.

(67) Chauvin, A.; Gumy, F.; Imbert, D.; Bünzli, J.-C. G. Erratum: Europium and Terbium Tris (Dipicolinates) as Secondary Standards for Quantum Yield Determination. *Spectrosc. Lett.* **2007**, *40*, 193.

(68) Enomoto, K.; LaVerne, J. A.; Seki, S.; Tagawa, S. Formation and Decay of the Triplet Excited State of Pyridine. *J. Phys. Chem. A* **2006**, *110*, 9874–9879.

(69) Latva, M.; Takalob, H.; Mikkala, V.-M.; Matachescu, C.; Rodriguez-Ubis, J. C.; Kankarea, J. Correlation between the Lowest Triplet State Energy Level of the Ligand and Lanthanide(III) Luminescence Quantum Yield. *J. Lumin.* **1997**, *75*, 149–16921.

(70) Nonat, A.; Gateau, C.; Fries, P. H.; Mazzanti, M. Lanthanide Complexes of a Picolinate Ligand Derived from 1,4,7-Triazacyclononane with Potential Application in Magnetic Resonance Imaging and Time-Resolved Luminescence Imaging. *Chem. - Eur. J.* **2006**, *12*, 7133–7150.

(71) Nocton, G.; Nonat, A.; Gateau, C.; Mazzanti, M. Water Stability and Luminescence of Lanthanide Complexes of Tripodal Ligands Derived from 1,4,7-Triazacyclononane: Pyridinecarboxamide versus Pyridinecarboxylate Donors. *Helv. Chim. Acta* **2009**, *92*, 2257–2273.

(72) Regueiro-Figueroa, M.; Bensenane, B.; Ruscsák, E.; Esteban-Gómez, D.; Charbonnière, L. J.; Tircsó, G.; Tóth, I.; Blas, A.; de Rodríguez-Blas, T.; Platas-Iglesias, C. Lanthanide DOTA-like Complexes Containing a Picolinate Pendant: Structural Entry for the Design of Ln^{III}-Based Luminescent Probes. *Inorg. Chem.* **2011**, *50*, 4125–4141.

(73) Guanci, C.; Giovenzana, G.; Lattuada, L.; Platas-Iglesias, C.; Charbonnière, L. J. AMPED: A New Platform for Picolinate Based Luminescent Lanthanide Chelates. *Dalton Trans.* **2015**, *44*, 7654–7661.

(74) Cosby, A. G.; Quevedo, G.; Boros, E. A High-Throughput Method To Measure Relative Quantum Yield of Lanthanide Complexes for Bioimaging. *Inorg. Chem.* **2019**, *58*, 10611–10615.

(75) Werts, M. H. V.; Jukes, R. T. F.; Verhoeven, J. W. The Emission Spectrum and the Radiative Lifetime of Eu³⁺ in Luminescent Lanthanide Complexes. *Phys. Chem. Chem. Phys.* **2002**, *4*, 1542–1548.

(76) Shavaleev, N. M.; Eliseeva, S. V.; Scopelliti, R.; Bünzli, J.-C. G. Influence of Symmetry on the Luminescence and Radiative Lifetime of Nine-Coordinate Europium Complexes. *Inorg. Chem.* **2015**, *54*, 9166–9173.

(77) Leygue, N.; Picard, C.; Faure, P.; Bourrier, E.; Lamarque, L.; Zwier, J. M.; Galaup, C. Design of Novel Tripyridinophane-Based Eu(III) Complexes as Efficient Luminescent Labels for Bioassay Applications. *Org. Biomol. Chem.* **2021**, *20*, 182–195.

(78) Piccinelli, F.; Rosa, C. D.; Melchior, A.; Faura, G.; Tolazzi, M.; Bettinelli, M. Eu(III) and Tb(III) Complexes of 6-Fold Coordinating Ligands Showing High Affinity for the Hydrogen Carbonate Ion: A Spectroscopic and Thermodynamic Study. *Dalton Trans.* **2019**, *48*, 1202–1216.

(79) Di Pietro, S.; Iacopini, D.; Moscardini, A.; Bizzarri, R.; Pineschi, M.; Di Bussolo, V.; Signore, G. New Coumarin Dipicolinate Europium Complexes with a Rich Chemical Speciation and Tunable Luminescence. *Molecules* **2021**, *26*, 1265.

(80) Isaac, M.; Denisov, S. A.; McClenaghan, N. D.; Sénèque, O. Bioinspired Luminescent Europium-Based Probe Capable of Discrimination between Ag⁺ and Cu⁺. *Inorg. Chem.* **2021**, *60*, 10791–10798.

(81) Kofod, N.; Nielsen, L. G.; Sørensen, T. J. Temperature Dependence of Fundamental Photophysical Properties of [Eu(MeOH-*d*₄)₉]³⁺ Solvates and [Eu(DOTA(MeOH-*d*₄))][−] Complexes. *J. Phys. Chem. A* **2021**, *125*, 8347–8357.

(82) Xing, Y.; Jindal, A. K.; Regueiro-Figueroa, M.; Le Fur, M.; Kervarec, N.; Zhao, P.; Kovacs, Z.; Valencia, L.; Pérez-Lourido, P.; Tripier, R.; Esteban-Gómez, D.; Platas-Iglesias, C.; Sherry, A. D. The Relationship between NMR Chemical Shifts of Thermally Polarized and Hyperpolarized ⁸⁹Y Complexes and Their Solution Structures. *Chem. - Eur. J.* **2016**, *22*, 16657–16667.

(83) Tircsó, G.; Kovács, Z.; Sherry, A. D. Equilibrium and Formation/Dissociation Kinetics of Some Ln^{III}PCTA Complexes. *Inorg. Chem.* **2006**, *45*, 9269–9280.

(84) Burai, L.; Fábrián, I.; Király, R.; Szilágyi, E.; Brücher, E. Equilibrium and Kinetic Studies on the Formation of the Lanthanide-(III) Complexes, [Ce(Dota)][−] and [Yb(Dota)][−] (H₄dota = 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid). *J. Chem. Soc., Dalton Trans.* **1998**, *No 2*, 243–248.

(85) Pulukkody, K. P.; Norman, T. J.; Parker, D.; Royle, L.; Broan, C. J. Synthesis of Charged and Uncharged Complexes of Gadolinium and Yttrium with Cyclic Polyazaphosphinic Acid Ligands for in Vivo Applications. *J. Chem. Soc., Perkin Trans. 2* **1993**, *No 4*, 605.

(86) Tircsó, G.; Benyó, E. T.; Suh, E. H.; Jurek, P.; Kiefer, G. E.; Sherry, A. D.; Kovács, Z. (S)-5-(*p*-Nitrobenzyl)-PCTA, a Promising Bifunctional Ligand with Advantageous Metal Ion Complexation Kinetics. *Bioconjugate Chem.* **2009**, *20*, 565–575.

(87) Pandey, U.; Mukherjee, A.; Sarma, H. D.; Das, T.; Pillai, M. R. A.; Venkatesh, M. Evaluation of ⁹⁰Y-DTPA and ⁹⁰Y-DOTA for Potential Application in Intra-Vascular Radionuclide Therapy. *Appl. Radiat. Isot.* **2002**, *57*, 313–318.

(88) APEX3, Version 2016.1.; Bruker AXS Inc., 2016.

(89) SAINT, Version 8.37A; Bruker AXS Inc., 2015.

(90) Sheldrick, G. M. SADABS, Version 2014/5; Bruker AXS Inc.

(91) Sheldrick, G. M. Crystal Structure Refinement with SHELXL. *Acta Crystallogr., Sect. C: Struct. Chem.* **2015**, *71*, 3–8.

(92) Sheldrick, G. M. A Short History of SHELX. *Acta Crystallogr., Sect. A: Found. Crystallogr.* **2008**, *64*, 112–122.

(93) Tao, J.; Perdew, J. P.; Staroverov, V. N.; Scuseria, G. E. Climbing the Density Functional Ladder: Nonempirical Meta-Generalized Gradient Approximation Designed for Molecules and Solids. *Phys. Rev. Lett.* **2003**, *91*, No. 146401.

(94) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery, J. A., Jr; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. *Gaussian 09*, Revision D.01.

(95) Andrae, D.; Häußermann, U.; Dolg, M.; Stoll, H.; Preuß, H. Energy-Adjusted Ab Initio Pseudopotentials for the Second and Third Row Transition Elements. *Theor. Chim. Acta* **1990**, *77*, 123–141.

(96) Martin, J. M. L.; Sundermann, A. Correlation Consistent Valence Basis Sets for Use with the Stuttgart–Dresden–Bonn Relativistic Effective Core Potentials: The Atoms Ga–Kr and In–Xe. *J. Chem. Phys.* **2001**, *114*, 3408–3420.

(97) Dolg, M.; Stoll, H.; Savin, A.; Preuss, H. Energy-Adjusted Pseudopotentials for the Rare Earth Elements. *Theor. Chim. Acta* **1989**, *75*, 173–194.

(98) Tomasi, J.; Mennucci, B.; Cammi, R. Quantum Mechanical Continuum Solvation Models. *Chem. Rev.* **2005**, *105*, 2999–3094.

(99) Dennington, R.; Keith, T.; Millam, J. *GaussView 5*, 2009.

(100) Neese, F. The ORCA Program System. *WIREs Comput. Mol. Sci.* **2012**, *2*, 73–78.

(101) Neese, F. Software Update: The ORCA Program System, Version 4.0. *WIREs Comput. Mol. Sci.* **2018**, *8*, No. e1327.

(102) Ditchfield, R. Molecular Orbital Theory of Magnetic Shielding and Magnetic Susceptibility. *J. Chem. Phys.* **1972**, *56*, 5688–5691.

(103) Helgaker, T.; Jaszunski, M.; Ruud, K. Ab Initio Methods for the Calculation of NMR Shielding and Indirect Spin–Spin Coupling Constants. *Chem. Rev.* **1999**, *99*, 293–352.

(104) Barysz, M.; Sadlej, A. J. Two-Component Methods of Relativistic Quantum Chemistry: From the Douglas–Kroll Approximation to the Exact Two-Component Formalism. *J. Mol. Struct.: THEOCHEM* **2001**, *573*, 181–200.

(105) Reiher, M. Douglas–Kroll–Hess Theory: A Relativistic Electrons-Only Theory for Chemistry. *Theor. Chem. Acc.* **2006**, *116*, 241–252.

(106) Ahlrichs, R.; May, K. Contracted All-Electron Gaussian Basis Sets for Atoms Rb to Xe. *Phys. Chem. Chem. Phys.* **2000**, *2*, 943–945.

(107) Kossmann, S.; Neese, F. Comparison of Two Efficient Approximate Hartree–Fock Approaches. *Chem. Phys. Lett.* **2009**, *481*, 240–243.

(108) Weigend, F.; Kattannek, M.; Ahlrichs, R. Approximated Electron Repulsion Integrals: Cholesky Decomposition versus Resolution of the Identity Methods. *J. Chem. Phys.* **2009**, *130*, No. 164106.

(109) Stoychev, G. L.; Auer, A. A.; Izsák, R.; Neese, F. Self-Consistent Field Calculation of Nuclear Magnetic Resonance Chemical Shielding Constants Using Gauge-Including Atomic Orbitals and Approximate Two-Electron Integrals. *J. Chem. Theory Comput.* **2018**, *14*, 619–637.

(110) Stoychev, G. L.; Auer, A. A.; Neese, F. Automatic Generation of Auxiliary Basis Sets. *J. Chem. Theory Comput.* **2017**, *13*, 554–562.

(111) Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric

Constant and Atomic Surface Tensions. *J. Phys. Chem. B* **2009**, *113*, 6378–6396.

Recommended by ACS

Lanthanide(III) Complexes Based on an 18-Membered Macrocyclic Containing Acetamide Pendants. Structural Characterization and paraCEST Properties

Goretti Castro, Paulo Pérez-Lourido, *et al.*

JANUARY 20, 2021
INORGANIC CHEMISTRY

READ 

Expanding the Scope of PycLen-Picolinate Lanthanide Chelates to Potential Theranostic Applications

Gwladys Nizou, Raphaël Tripiet, *et al.*

JULY 30, 2020
INORGANIC CHEMISTRY

READ 

Expanding the Family of PycLen-Based Ligands Bearing Pendant Picolinate Arms for Lanthanide Complexation

Mariane Le Fur, Carlos Platas-Iglesias, *et al.*

MAY 30, 2018
INORGANIC CHEMISTRY

READ 

Lanthanide Complexes with 1H paraCEST and 19F Response for Magnetic Resonance Imaging Applications

Rosa Pujales-Paradela, Carlos Platas-Iglesias, *et al.*

MAY 16, 2019
INORGANIC CHEMISTRY

READ 

Get More Suggestions >